Selecta Biosciences Announces New Preclinical Gene Therapy Data at the Annual Meeting of the American Society of … – GlobeNewswire (press release)
|
Selecta Biosciences Announces New Preclinical Gene Therapy Data at the Annual Meeting of the American Society of …
GlobeNewswire (press release) “Immunogenicity is a key challenge in gene therapy, limiting the number of diseases and patients that can be effectively treated and presenting a safety hurdle,” said Werner Cautreels, Ph.D., CEO and Chairman of Selecta. “Together with various … |
